Clinical Data & Safety

HELP PROTECT YOUR PATIENTS WITH TEZSPIRE

Not an actual patient.
For illustrative purposes only.

 

In an overall population:

Significant exacerbation reductions versus placebo (PATHWAY 71%, NAVIGATOR 56%, P<0.001) (primary endpoint); 230 mL improvement in lung function versus baseline (NAVIGATOR, secondary endpoint)1-3*

In patients with multiple drivers and triggers:

POST HOC ANALYSIS

EOS 300 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING4†

79% Icon

reduction in exacerbations from baseline‡§

TEZSPIRE + SOC (n=181) Baseline 2.96 vs EOT 0.63

EOS 450 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

82% Icon

reduction in exacerbations from baseline‡II

TEZSPIRE + SOC (n=98) Baseline 2.96 vs EOT 0.52

EOS 150-299 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

77% Icon

reduction in exacerbations from baseline‡¶

TEZSPIRE + SOC (n=137) Baseline 2.60 vs EOT 0.60

Results are descriptive only. Definitive conclusions cannot be made.

See patient profiles

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% Cl: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% Cl: 0.37-0.53).1

†Allergic status as defined by a serum IgE result specific to any perennial aeroallergen in the FEIA panel.4,5

‡Baseline is defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).4,5

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 2.94 and EOT 1.88 (n=179; 36% reduction from baseline).4‡

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 3.10 and EOT 2.20 (n=106; 29% reduction from baseline).5‡

Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 2.42 and EOT 1.28 (n=132; 47% reduction from baseline).5‡

AAER=annualized asthma exacerbation rate; CI=confidence interval; EOS=eosinophils; EOT=end of treatment; ER=emergency room; FEIA=fluorescence enzyme immunoassay; IgE=immunoglobulin E; RR=rate ratio; SOC=standard of care.

POST HOC ANALYSIS

EOS 300 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING4†

93% Icon

reduction from baseline in exacerbations requiring hospitalizations, urgent care, or ED visits‡§

TEZSPIRE + SOC (n=181) Baseline 0.44 vs EOT 0.03

EOS 450 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

92% Icon

reduction from baseline in exacerbations requiring hospitalizations, urgent care, or ED visits‡II

TEZSPIRE + SOC (n=98) Baseline 0.38 vs EOT 0.03

EOS 150-299 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

96% Icon

reduction from baseline in exacerbations requiring hospitalizations, urgent care, or ED visits‡¶

TEZSPIRE + SOC (n=137) Baseline 0.47 vs EOT 0.02

Results are descriptive only. Definitive conclusions cannot be made.

See patient profiles

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% Cl: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% Cl: 0.37-0.53).1

†Allergic status as defined by a serum IgE result specific to any perennial aeroallergen in the FEIA panel.4,5

‡Baseline is defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).4,5

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.47 and EOT 0.23 (n=179; 51% reduction from baseline).4‡

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.56 and EOT 0.29 (n=106; 48% reduction from baseline).5‡

Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.33 and EOT 0.11 (n=132; 67% reduction from baseline).5‡

AAER=annualized asthma exacerbation rate; CI=confidence interval; ED=emergency department; EOS=eosinophils; EOT=end of treatment; ER=emergency room; FEIA=fluorescence enzyme immunoassay; IgE=immunoglobulin E; RR=rate ratio; SOC=standard of care.

POST HOC ANALYSIS

EOS 300 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING4†

370 Milliliters Icon

improvement in FEV1 from baseline‡

TEZSPIRE + SOC (n=171)

EOS 450 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

440 Milliliters Icon

improvement in FEV1 from baseline§

TEZSPIRE + SOC (n=98)

EOS 150-299 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

120 Milliliters Icon

improvement in FEV1 from baselineII

TEZSPIRE + SOC (n=134)

Results are descriptive only. Definitive conclusions cannot be made.

See patient profiles

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% Cl: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% Cl: 0.37-0.53).1

†Allergic status as defined by a serum IgE result specific to any perennial aeroallergen in the FEIA panel.4,5

‡Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 160 mL (n=165); LS mean difference between groups 210 mL (95% Cl: 120-290).4

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 200 mL (n=106); LS mean difference between groups 240 mL (95% Cl: 130-350).5

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 100 mL (n=132); LS mean difference between groups 20 mL (95% Cl: -70-120).5

AAER=annualized asthma exacerbation rate; CI=confidence interval; EOS=eosinophils; FEIA=fluorescence enzyme immunoassay; FEV1=forced expiratory volume in 1 second; IgE=immunoglobulin E; LS=least-squares; RR=rate ratio; SOC=standard of care.

EXACERBATION REDUCTION DATA BY Key Trigger Types and Seasons VS PLACEBO6,7†‡

By key trigger types6†

Exacerbation Data by Trigger Types Chart

Post hoc analysis of the NAVIGATOR clinical trial. Results are descriptive only. Definitive conclusions cannot be made.

 

By seasons7‡

Exacerbation Data by Seasons Chart

Post hoc analysis of the PATHWAY clinical trial. Results are descriptive only. Definitive conclusions cannot be made.

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% Cl: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% Cl: 0.37-0.53).1

†95% confidence intervals for exacerbation rates for placebo, TEZSPIRE, and percent reduction between groups. Infection: placebo 0.49 (0.41-0.57), TEZSPIRE 0.28 (0.23-0.35), reduction 41% (24-55). Allergen exposure: placebo 0.14 (0.10-0.20), TEZSPIRE 0.04 (0.02-0.07), reduction 71% (47-84). Other: placebo 0.27 (0.20-0.36), TEZSPIRE 0.14 (0.10-0.20), reduction 47% (20-65). Unknown: placebo 1.03 (0.86-1.24), TEZSPIRE 0.40 (0.32-0.49), reduction 62% (49-71). Analyses were not performed on exacerbation reductions to individual triggers within the ‘other’ category.6

‡95% confidence intervals for exacerbation rates for placebo, TEZSPIRE, and percent reduction between groups. Fall: placebo 0.73 (0.47-1.08), TEZSPIRE 0.25
(0.11-0.49), reduction 67% (21-86). Winter: placebo 0.87 (0.58-1.24), TEZSPIRE 0.32 (0.15-0.58), reduction 64% (22-83). Spring: placebo 0.62 (0.39-0.95), TEZSPIRE 0.13 (0.03-0.33), reduction 80% (41-93). Summer: placebo 0.67 (0.43-1.01), TEZSPIRE 0.12 (0.03-0.32), reduction 82% (48-94). Data from patients in the southern hemisphere were transformed to align with equivalent seasonal time periods in the northern hemisphere by shifting the data by 6 months.7

AAER=annualized asthma exacerbation rate; CI=confidence interval; RR=rate ratio; SOC=standard of care.

POST HOC ANALYSIS

EOS 300 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING4†

79% Icon

reduction in exacerbations from baseline‡§

TEZSPIRE + SOC (n=181) Baseline 2.96 vs EOT 0.63

EOS 450 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

82% Icon

reduction in exacerbations from baseline‡II

TEZSPIRE + SOC (n=98) Baseline 2.96 vs EOT 0.52

EOS 150-299 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

77% Icon

reduction in exacerbations from baseline‡¶

TEZSPIRE + SOC (n=137) Baseline 2.60 vs EOT 0.60

Results are descriptive only. Definitive conclusions cannot be made.

See patient profiles

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% Cl: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% Cl: 0.37-0.53).1

†Allergic status as defined by a serum IgE result specific to any perennial aeroallergen in the FEIA panel.4,5

‡Baseline is defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).4,5

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 2.94 and EOT 1.88 (n=179; 36% reduction from baseline).4‡

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 3.10 and EOT 2.20 (n=106; 29% reduction from baseline).5‡

Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 2.42 and EOT 1.28 (n=132; 47% reduction from baseline).5‡

AAER=annualized asthma exacerbation rate; CI=confidence interval; EOS=eosinophils; EOT=end of treatment; ER=emergency room; FEIA=fluorescence enzyme immunoassay; IgE=immunoglobulin E; RR=rate ratio; SOC=standard of care.

POST HOC ANALYSIS

EOS 300 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING4†

93% Icon

reduction from baseline in exacerbations requiring hospitalizations, urgent care, or ED visits‡§

TEZSPIRE + SOC (n=181) Baseline 0.44 vs EOT 0.03

EOS 450 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

92% Icon

reduction from baseline in exacerbations requiring hospitalizations, urgent care, or ED visits‡II

TEZSPIRE + SOC (n=98) Baseline 0.38 vs EOT 0.03

EOS 150-299 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

96% Icon

reduction from baseline in exacerbations requiring hospitalizations, urgent care, or ED visits‡¶

TEZSPIRE + SOC (n=137) Baseline 0.47 vs EOT 0.02

Results are descriptive only. Definitive conclusions cannot be made.

See patient profiles

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% Cl: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% Cl: 0.37-0.53).1

†Allergic status as defined by a serum IgE result specific to any perennial aeroallergen in the FEIA panel.4,5

‡Baseline is defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).4,5

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.47 and EOT 0.23 (n=179; 51% reduction from baseline).4‡

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.56 and EOT 0.29 (n=106; 48% reduction from baseline).5‡

Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.33 and EOT 0.11 (n=132; 67% reduction from baseline).5‡

AAER=annualized asthma exacerbation rate; CI=confidence interval; ED=emergency department; EOS=eosinophils; EOT=end of treatment; ER=emergency room; FEIA=fluorescence enzyme immunoassay; IgE=immunoglobulin E; RR=rate ratio; SOC=standard of care.

POST HOC ANALYSIS

EOS 300 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING4†

370 Milliliters Icon

improvement in FEV1 from baseline‡

TEZSPIRE + SOC (n=171)

EOS 450 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

440 Milliliters Icon

improvement in FEV1 from baseline§

TEZSPIRE + SOC (n=98)

EOS 150-299 CELLS/μLWITH POSITIVEAEROALLERGEN TESTING5†

120 Milliliters Icon

improvement in FEV1 from baselineII

TEZSPIRE + SOC (n=134)

Results are descriptive only. Definitive conclusions cannot be made.

See patient profiles

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% Cl: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% Cl: 0.37-0.53).1

†Allergic status as defined by a serum IgE result specific to any perennial aeroallergen in the FEIA panel.4,5

‡Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 160 mL (n=165); LS mean difference between groups 210 mL (95% Cl: 120-290).4

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 200 mL (n=106); LS mean difference between groups 240 mL (95% Cl: 130-350).5

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 100 mL (n=132); LS mean difference between groups 20 mL (95% Cl: -70-120).5

AAER=annualized asthma exacerbation rate; CI=confidence interval; EOS=eosinophils; FEIA=fluorescence enzyme immunoassay; FEV1=forced expiratory volume in 1 second; IgE=immunoglobulin E; LS=least-squares; RR=rate ratio; SOC=standard of care.

EXACERBATION REDUCTION DATA BY Key Trigger Types and Seasons VS PLACEBO6,7†‡

By key trigger types6†

Exacerbation Data by Trigger Types Chart

Post hoc analysis of the NAVIGATOR clinical trial. Results are descriptive only. Definitive conclusions cannot be made.

 

By seasons7‡

Exacerbation Data by Seasons Chart

Post hoc analysis of the PATHWAY clinical trial. Results are descriptive only. Definitive conclusions cannot be made.

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% Cl: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% Cl: 0.37-0.53).1

†95% confidence intervals for exacerbation rates for placebo, TEZSPIRE, and percent reduction between groups. Infection: placebo 0.49 (0.41-0.57), TEZSPIRE 0.28 (0.23-0.35), reduction 41% (24-55). Allergen exposure: placebo 0.14 (0.10-0.20), TEZSPIRE 0.04 (0.02-0.07), reduction 71% (47-84). Other: placebo 0.27 (0.20-0.36), TEZSPIRE 0.14 (0.10-0.20), reduction 47% (20-65). Unknown: placebo 1.03 (0.86-1.24), TEZSPIRE 0.40 (0.32-0.49), reduction 62% (49-71). Analyses were not performed on exacerbation reductions to individual triggers within the ‘other’ category.6

‡95% confidence intervals for exacerbation rates for placebo, TEZSPIRE, and percent reduction between groups. Fall: placebo 0.73 (0.47-1.08), TEZSPIRE 0.25
(0.11-0.49), reduction 67% (21-86). Winter: placebo 0.87 (0.58-1.24), TEZSPIRE 0.32 (0.15-0.58), reduction 64% (22-83). Spring: placebo 0.62 (0.39-0.95), TEZSPIRE 0.13 (0.03-0.33), reduction 80% (41-93). Summer: placebo 0.67 (0.43-1.01), TEZSPIRE 0.12 (0.03-0.32), reduction 82% (48-94). Data from patients in the southern hemisphere were transformed to align with equivalent seasonal time periods in the northern hemisphere by shifting the data by 6 months.7

AAER=annualized asthma exacerbation rate; CI=confidence interval; RR=rate ratio; SOC=standard of care.

border-line

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% Cl: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% Cl: 0.37-0.53).1

AAER=annualized asthma exacerbation rate; CI=confidence interval, RR=rate ratio; SOC=standard of care.

TEZSPIRE Clinical Data Tool Tablet

EXPLORE DATA IN MORE PATIENTS 
WITH MULTIPLE DRIVERS OF DISEASE

TRY OUR CLINICAL DATA TOOL 
 

Back

FAQs

Next

Safety

Important Safety Information

Collapse

CONTRAINDICATIONS

Known hypersensitivity to tezepelumab-ekko or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.

Acute Asthma Symptoms or Deteriorating Disease

TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.

Abrupt Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

Live Attenuated Vaccines

The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥3%) are pharyngitis, arthralgia, and back pain.

USE IN SPECIFIC POPULATIONS

There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

INDICATION

TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.


TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.

Please see full Prescribing Information, including
Patient Information and Instructions for Use.

You may report side effects related to AstraZeneca products.Opens new window

Important Safety Information

 +

Important Safety Information

Collapse

CONTRAINDICATIONS

Known hypersensitivity to tezepelumab-ekko or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.

Acute Asthma Symptoms or Deteriorating Disease

TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.

Abrupt Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

Live Attenuated Vaccines

The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥3%) are pharyngitis, arthralgia, and back pain.

USE IN SPECIFIC POPULATIONS

There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

INDICATION

TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.


TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.

Please see full Prescribing Information, including
Patient Information and Instructions for Use.

You may report side effects related to AstraZeneca products.Opens new window

Important Safety Information

 +

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2.  Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19)(suppl):1-60.

Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.

References: 1. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.

References: 1. Data on File. REF-91518, AstraZeneca Pharmaceuticals LP. 2. Data on File. REF-US-100158, AstraZeneca Pharmaceuticals LP. 3. Data on File. REF-87321, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 3. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 4. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma [supplement]. N Engl J Med. 2021;384(19):1800-1809.

References: 1. Chipps BE, Soong W, Panettieri R Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 4. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 5. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 6. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236.

References: 1. Data on File. REF- 134673, AstraZeneca Pharmaceuticals LP. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 5. Menzies-Gow A, Corren J, Israel E, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma and co-morbid nasal polyps in NAVIGATOR. Poster presented at: European Respiratory Society (ERS) International Congress; September 5-8, 2021; Sheffield, UK. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 7. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997-1009. 8. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 9. Nordenmark LH, Hellqvist Å, Emson C, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2(10):1-10. 10. Data on File. REF-176078, AstraZeneca Pharmaceuticals LP. 11. Data on File. REF-188753, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 5. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 6. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 7. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Corren J, Parnes JR, Wang L, et al. Appendix to: Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(suppl):1-54. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60. 6. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double- blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 7. Data on File. REF-148822, AstraZeneca Pharmaceuticals LP. 8. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 5. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.

References: 1. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 7. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 8. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP. 9. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 10. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 11. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 13. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 14. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 15. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11. 16. Data on File. REF-91518, AstraZeneca Pharmaceuticals LP. 17. Data on File. US-100158, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2.  Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19)(suppl):1-60.

Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.

References: 1. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.

References: 1. Data on File. REF-91518, AstraZeneca Pharmaceuticals LP. 2. Data on File. REF-US-100158, AstraZeneca Pharmaceuticals LP. 3. Data on File. REF-87321, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 3. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 4. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma [supplement]. N Engl J Med. 2021;384(19):1800-1809.

References: 1. Chipps BE, Soong W, Panettieri R Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 4. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 5. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 6. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236.

References: 1. Data on File. REF- 134673, AstraZeneca Pharmaceuticals LP. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 5. Menzies-Gow A, Corren J, Israel E, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma and co-morbid nasal polyps in NAVIGATOR. Poster presented at: European Respiratory Society (ERS) International Congress; September 5-8, 2021; Sheffield, UK. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 7. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997-1009. 8. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 9. Nordenmark LH, Hellqvist Å, Emson C, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2(10):1-10. 10. Data on File. REF-176078, AstraZeneca Pharmaceuticals LP. 11. Data on File. REF-188753, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 5. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 6. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 7. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Corren J, Parnes JR, Wang L, et al. Appendix to: Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(suppl):1-54. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60. 6. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double- blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 7. Data on File. REF-148822, AstraZeneca Pharmaceuticals LP. 8. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 5. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.

References: 1. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 7. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 8. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP. 9. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 10. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 11. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 13. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 14. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 15. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11. 16. Data on File. REF-91518, AstraZeneca Pharmaceuticals LP. 17. Data on File. US-100158, AstraZeneca Pharmaceuticals LP.

This product information is intended for US Healthcare Professionals only.

TEZSPIRE is a registered trademark of Amgen Inc.
and AstraZeneca.
©2024 AstraZeneca. All rights reserved. US-79076 Last Updated 10/24